Abstract 359P
Background
Although engaging in exercise after breast cancer surgery (BCS) has been shown to facilitate faster recovery, factors influencing exercise participation during the early recovery phase remain unclear in breast cancer patients. Therefore, this study aimed to explore the perceptions, attitudes, and barriers to exercise in breast cancer patients immediately after surgery and up to 4 weeks post-surgery.
Methods
A descriptive qualitative research method was employed to investigate this topic. A purposive sample of 33 breast cancer patients was selected, and each participant was interviewed three times over a one-month period after surgery.
Results
We found physical constraints and psychological resistance were identified as barriers to exercise. Postoperative physical symptoms (pain, range of motion, lack of fitness, and seroma) and surgical drains were identified as physical constraints. Participants also faced psychological resistance such as concerns about side effects, lack of willpower, and fear of pain. Furthermore, a lack of trustworthy information regarding the timing of exercise initiation and proper types of exercise after surgery was identified as a psychological resistance. Table: 359P
Themes, codes, and categories from the interviews
Categories | %(n) | Codes | %(n) | Theme | %(n) |
Physical constraints | 100% (33) | Postoperative physical symptoms | 100% (33) | Pain at the surgery site | 87.9% (29) |
Limited range of motion | 66.6% (22) | ||||
Lack of fitness | 33.3% (11) | ||||
Seroma | 12.2% (4) | ||||
Operation derived condition | 45.4% (15) | Drain | 45.5% (15) | ||
Psychological resistance | 48.5% (16) | Perception and attitude | 54.5% (18) | Concerns about side effects | 42.4% (13) |
Lack of willpower | 15.2% (5) | ||||
Fear of pain | 15.2% (5) | ||||
Concerns due to lack of trustworthy exercise information | 54.5% (18) | Concerns regarding the exercise timing being inappropriate | 42.4% (14) | ||
Discouragement from others | 18.2% (6) |
Conclusions
The identified barriers, both physical and psychological, should be taken into consideration when developing strategies to motivate and support patients in engaging in exercise. The identified barriers, both physical and psychological, should be taken into consideration when developing strategies to motivate and support patients in engaging in exercise.
Clinical trial identification
This study involves human participants and was approved by the Institutional Review Board of Severance Hospital (IRB No. 4-2018-1094).
Editorial acknowledgement
This work was supported by the National Research Foundation of Korea grant number NRF-2017S1A5A2A01024689, NRF-2021S1A5B5A16077404, the National R&D Programme for Cancer Control, Ministry of Health and Welfare, Republic of Korea (HA21C0067000021) and the Yonsei Signature Research Cluster Programme 2021220009.
Legal entity responsible for the study
The authors.
Funding
This work was supported by the National Research Foundation of Korea grant number NRF-2017S1A5A2A01024689, NRF-2021S1A5B5A16077404, the National R&D Programme for Cancer Control, Ministry of Health and Welfare, Republic of Korea (HA21C0067000021) and the Yonsei Signature Research Cluster Programme 2021220009.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
403P - Breast cancer specific survival (BCSS) in HR+/HER2- metastatic breast cancer (mBC) from 2010 to 2019
Presenter: Adam Brufsky
Session: Poster session 03
404P - A multicenter, single-arm, open-label trial of birociclib, a CDK4/6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer
Presenter: Jiayu Wang
Session: Poster session 03
405P - E7389-LF as a first-line (1L) chemotherapy for patients (pts) with metastatic/advanced HER2-negative breast cancer (HER2− BC): Results from a phase I study dose-expansion part
Presenter: Kan Yonemori
Session: Poster session 03
406P - Phase Ib safety and efficacy of nadunolimab/gemcitabine/carboplatin in mTNBC
Presenter: Sara Lopez-Tarruella Cobo
Session: Poster session 03
407P - Palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer patients: Interim results of the PERFORM study
Presenter: Julia C. Radosa
Session: Poster session 03
408P - Proxalutamide plus endocrine therapy as a combination therapy in women with HR+/HER2-/AR+ metastatic breast cancer: A phase I study
Presenter: Huiping Li
Session: Poster session 03
410P - Patients treated with pertuzumab followed by T-DM1 for breast cancer in France from 2014 to 2021: A survival analysis of 10,408 patients from the French National Hospital discharge summary database (PMSI)
Presenter: Josephine Lemaitre
Session: Poster session 03
411P - Therapy management and safety of 1st-line ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in clinical routine: Real-world data from the RIBANNA study (5th interim analysis (IA))
Presenter: Frederik Marmé
Session: Poster session 03
412P - Sacituzumab govitecan versus chemotherapy for metastatic breast cancer: A meta-analysis on safety outcomes
Presenter: Alessandro Rizzo
Session: Poster session 03